Worldwide: The Global IP Scorecard For Pharma & Biotech Compulsory Licenses

Last Updated: 22 October 2007
Article by Duncan Bucknell

Please feel free to add to or comment on the scorecard at

Countries, Products, Timing And Updates

There's been a lot of buzz lately about various developing countries ordering Compulsory Licenses. This scorecard tracks the countries, the products, timing of the ordered Licenses and provides updates as they arise.

Compulsory Licenses, (under Article 31 of TRIPS) have traditionally been ordered to enable access to medicines to people in developing countries who would otherwise not be able to afford them. The Licenses have typically been granted in respect of medicines to treat diseases such HIV/AIDS and other infectious diseases.

Part of the buzz which has recently arisen surrounds allegations that some countries have used the mechanism to drive down drug prices.

Other similar mechanisms, such as those under the 'Paragraph 6' system are also be tracked in this Scorecard. The Paragraph 6 system was implemented in the 30 August 2003 Decision of the WTO. Paragraph 6 refers to Paragraph 6 of the DOHA Declaration on TRIPS. The mechanism basically enables importation of cheaper medicines for countries which are too poor to manufacture the medicines themselves. Paragraph 6 states:

"6. We recognize that WTO Members with insufficient or no manufacturing capacities in the pharmaceutical sector could face difficulties in making effective use of compulsory licensing under the TRIPS Agreement. We instruct the Council for TRIPS to find an expeditious solution to this problem and to report to the General Council before the end of 2002."

For a detailed report on Compulsory Licenses in many countries, see the Knowledge Ecxology International site.

For a nice summary of some recent developments up to 13 August 2007, see the Patent Docs blog.)

Background information on this case:

Article 31 of TRIPS states:

Article 31 Other Use Without Authorization of the Right Holder

Where the law of a Member allows for other use of the subject matter of a patent without the authorization of the right holder, including use by the government or third parties authorized by the government, the following provisions shall be respected:

  • authorization of such use shall be considered on its individual merits;
  • such use may only be permitted if, prior to such use, the proposed user has made efforts to obtain authorization from the right holder on reasonable commercial terms and conditions and that such efforts have not been successful within a reasonable period of time. This requirement may be waived by a Member in the case of a national emergency or other circumstances of extreme urgency or in cases of public non-commercial use. In situations of national emergency or other circumstances of extreme urgency, the right holder shall, nevertheless, be notified as soon as reasonably practicable. In the case of public non-commercial use, where the government or contractor, without making a patent search, knows or has demonstrable grounds to know that a valid patent is or will be used by or for the government, the right holder shall be informed promptly;
  • the scope and duration of such use shall be limited to the purpose for which it was authorized, and in the case of semi-conductor technology shall only be for public non-commercial use or to remedy a practice determined after judicial or administrative process to be anti-competitive;
  • such use shall be non-exclusive;
  • such use shall be non-assignable, except with that part of the enterprise or goodwill which enjoys such use;
  • any such use shall be authorized predominantly for the supply of the domestic market of the Member authorizing such use;
  • authorization for such use shall be liable, subject to adequate protection of the legitimate interests of the persons so authorized, to be terminated if and when the circumstances which led to it cease to exist and are unlikely to recur. The competent authority shall have the authority to review, upon motivated request, the continued existence of these circumstances;
  • the right holder shall be paid adequate remuneration in the circumstances of each case, taking into account the economic value of the authorization;
  • the legal validity of any decision relating to the authorization of such use shall be subject to judicial review or other independent review by a distinct higher authority in that Member;
  • any decision relating to the remuneration provided in respect of such use shall be subject to judicial review or other independent review by a distinct higher authority in that Member;
  • Members are not obliged to apply the conditions set forth in subparagraphs (b) and
  • where such use is permitted to remedy a practice determined after judicial or administrative process to be anti-competitive. The need to correct anti-competitive practices may be taken into account in determining the amount of remuneration in such cases. Competent authorities shall have the authority to refuse termination of authorization if and when the conditions which led to such authorization are likely to recur;
  • where such use is authorized to permit the exploitation of a patent ("the second patent") which cannot be exploited without infringing another patent ("the first patent"), the following additional conditions shall apply:
    • the invention claimed in the second patent shall involve an important technical advance of considerable economic significance in relation to the invention claimed in the first patent;
    • the owner of the first patent shall be entitled to a cross-licence on reasonable terms to use the invention claimed in the second patent; and
    • the use authorized in respect of the first patent shall be non-assignable except with the assignment of the second patent.

Updates by Country


Aug 14, 2007

18 October 2005

Argentina announces intention to grant Compulsory License for Tamiflu (Oseltamivir). It later transpires that the patent was never granted in Argentina.




Aug 14, 2007

6 July 2007

Brazil grants Compulsory License in relation to Abbott's Kaletra.



Aug 14, 2007

4 May 2007

Brazil grants a compulsory license for Merck's HIV/AIDS drug Efavirenz.




Oct 4, 2007

The WTO received from Canada, on 4 October 2007, the first notification from any government that it has authorized a company to make a generic version of a patented medicine for export under special WTO provisions agreed in 2003. The triple combination AIDS therapy drug, TriAvir, can now be made and exported to Rwanda, which is unable to manufacture the medicine itself.

Earlier, on 17 July, Rwanda informed the WTO that it intends to import 260,000 packs of TriAvir — a fixed-dose combination product of Zidovudine, Lamivudine and Nevirapine — over two years. The drug is to be made in Canada by Apotex, Inc and is called ApoTriavir by the manufacturer.

Links: WTO release; IPKat comment



Aug 14, 2007

14 May 2004

Canada amends its Patent law to allow Canadian manufacturers to export to countries which lack the ability to manufacture pharmaceuticals - but only in respect of drugs listed in Schedule 1 to the Act.

Drugs that have been aded to Schedule 1 include:

lamivudine nevirarpine zidovudine tablets

Tamiflu (oseltamivir)



Aug 14, 2007

October 18, 2001
Health Canada granted a Comulsory License in relation to the Bayer's ciprofloxacin and authorized generic manufacture to build a stockpile as protection against an attack of anthrax.




Aug 14, 2007


Petitions by local manufacturer (Acromax) for Compulsory License for Combivir (Lamivudine and AZT) refused, appealed and refused again.

GSK agrees to supply HIV/AIDS drugs at a discount.




Aug 14, 2007

5 June 2005

Eritrea issues compulsory licenses for importation into Eritrea of generic HIV-AIDS medicines




Aug 14, 2007

July 2007

European Union Trade Commissioner sends a letter to the Thai government, warning that it should not take further action to force drugmakers to drop drug prices.




Aug 14, 2007

October 2005

Ghana issues compulsory licenses for importation into Ghana of Indian generic HIV/AIDS medicines.




Aug 14, 2007

18 April 2005

Guinea issues compulsory licenses for importation on patents on drugs to treat HIV-AIDS




Aug 14, 2007

March 2007

Indonesia issues a compulsory license for patents on the AIDS drug efavirenz



Aug 14, 2007

5 October 2004

Indonesia issues a Compulsory License to manufacture generic versions of lamivudine and nevirapine (both HIV/AIDS drugs).




Aug 14, 2007

January 1992

Israel grants Compulsory License to manufacture Bio-Hep-B under Biogen patent. Biogen's appeal was unsuccessful.

The patent expired in 1999 before the Supreme Court ruled on the dispute.




Aug 14, 2007

21 March 2007

Italy grants Compulsory License in relation to Finasteride and related generic drugs for two years prior to the 2009 expiration of patent monopoly (Complementary Protection Certificate).



Korea, republic of

Aug 14, 2007

January 2002

Korea rejects application for Compulsory License of Novartis' Glivec.




Aug 14, 2007

29 September 2004

Malaysisa issues a compulsory license to import from India didanosine (ddI), zidovudine (AZT) and lamivudine zidovidine (Combivir).




Aug 14, 2007

5 April 5 2004

Mozambique's issues compulsory license for lamivudine, stavudine and nevirapine.




Jul 19, 2007

19 July 2007

Rwanda becomes the first country to notify the WTO that it intends to use the Paragraph 6 system (of the DOHA Declaration).

Paragraph 6 is designed for those countries that do not have the facilities to manufacture pharmaceuticals and so allows importation.

IPKat post

Notification protocol




Aug 14, 2007

April 2007

After weeks of negotiations and public debate (and statements about withdrawing drugs from Thailand), Abbott agrees to provide discounted AIDS drugs (Kaletra/Aluvia) to Thailand.



Feb 1, 2007

Thailand announces two more Compulsory Licenses, this time:

Plavix, a heart disease drug made by Bristol-Myers Squibb and Sanofi-Aventis.

Kaletra, an HIV/AIDS drug made by Abbott Laboratories



Dec 6, 2006

Thailand government issues a compulsory license on Merck's AIDS drug, Efavirenz. Thailand was criticised for failing to first contact Merck.



United states

Aug 14, 2007

30 April 2007

The US Trade Representative elevatesThailand the Priority Watch list in its annual 'Special 301' Report. The USTR cites a concern that the past year has been characterized by an overall deterioration in the protection and enforcement of IP in Thailand.
The Report then specifically cites the recent grant of Compulsory Licenses as further evidence of weakening respect for patents.




Aug 14, 2007

21 September 2004

Zambia issues a compulsory license for lamivudine, stavudine and nevirapine.




Aug 14, 2007

May 2002

Zimbabwe declares Period of Emergency which enables it to ignore antiretroviral drug patents for 6 months via a compulsory license.

In 2003, the period of emergency was extended by five years (until 31 December 2008).



The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions